Brokerages expect Revance Therapeutics Inc (NASDAQ:RVNC) to announce ($0.95) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Revance Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.98) and the highest estimate coming in at ($0.90). Revance Therapeutics reported earnings of ($1.01) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.9%. The business is expected to issue its next earnings results on Thursday, November 1st.

On average, analysts expect that Revance Therapeutics will report full year earnings of ($3.90) per share for the current financial year, with EPS estimates ranging from ($3.92) to ($3.89). For the next year, analysts anticipate that the firm will post earnings of ($3.99) per share, with EPS estimates ranging from ($4.22) to ($3.71). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Revance Therapeutics.

Revance Therapeutics (NASDAQ:RVNC) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.92) by ($0.02). The company had revenue of $0.69 million for the quarter, compared to the consensus estimate of $0.93 million. Revance Therapeutics had a negative return on equity of 63.30% and a negative net margin of 13,690.62%.

A number of brokerages recently commented on RVNC. Zacks Investment Research upgraded Revance Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. Cantor Fitzgerald set a $50.00 price objective on Revance Therapeutics and gave the stock a “buy” rating in a research note on Thursday, August 2nd. ValuEngine upgraded Revance Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 2nd. Finally, BidaskClub downgraded Revance Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, July 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $45.91.

In other news, CFO Lauren P. Silvernail sold 2,874 shares of the stock in a transaction on Tuesday, May 22nd. The stock was sold at an average price of $30.25, for a total value of $86,938.50. Following the completion of the transaction, the chief financial officer now owns 65,497 shares of the company’s stock, valued at $1,981,284.25. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 18.86% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Revance Therapeutics by 21.6% in the second quarter. BlackRock Inc. now owns 2,931,980 shares of the biopharmaceutical company’s stock worth $80,482,000 after purchasing an additional 521,536 shares in the last quarter. Millennium Management LLC grew its stake in shares of Revance Therapeutics by 46.8% in the first quarter. Millennium Management LLC now owns 1,494,441 shares of the biopharmaceutical company’s stock worth $46,029,000 after purchasing an additional 476,209 shares in the last quarter. Northern Trust Corp grew its stake in shares of Revance Therapeutics by 12.6% in the first quarter. Northern Trust Corp now owns 339,450 shares of the biopharmaceutical company’s stock worth $10,455,000 after purchasing an additional 38,045 shares in the last quarter. Fosun International Ltd bought a new position in shares of Revance Therapeutics in the first quarter worth $9,835,000. Finally, OppenheimerFunds Inc. bought a new position in shares of Revance Therapeutics in the first quarter worth $7,025,000. 93.01% of the stock is owned by institutional investors.

Shares of Revance Therapeutics opened at $26.50 on Friday, according to Marketbeat. The firm has a market cap of $997.32 million, a P/E ratio of -6.61 and a beta of 1.33. Revance Therapeutics has a 12 month low of $22.40 and a 12 month high of $37.45.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in phase III clinical trials to treat glabellar (frown) lines, as well as in phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis.

Further Reading: Book Value Per Share in Stock Trading

Get a free copy of the Zacks research report on Revance Therapeutics (RVNC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.